Compare Select Medical Holdings Corporation (SEM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Select Medical Holdings Corporation vs GeneDx Holdings Corp — how do they compare? Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Select Medical Holdings Corporation and GeneDx Holdings Corp are close in size by market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SEM | WGS | |
|---|---|---|
Market Cap | $2.05B | $1.80B |
Sector | Health | Technology |
52-Week High | $16.66 | $167.51 |
52-Week Low | $11.77 | $34.51 |
Enterprise Value | $5.01B | $1.80B |
Dividend Yield | 1.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day, following its recent acquisition completion by a consortium led by Robert A. Ortenzio and Martin F. at $16.50 per share. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported 2025 revenue of $5.45 billion with a net income margin of 2.42%, while valuation ratios like a P/E of 15.43 and P/S of 0.36 appear reasonable. Recent earnings show two misses in the last three quarters against expectations.
The investment outlook is dominated by the completed acquisition, effectively capping upside near the $16.50 deal price. Risks include ongoing shareholder litigation alleging fiduciary breaches by the board regarding the buyout fairness. Analyst sentiment is neutral with a Hold-heavy consensus, while the stock's future price action will largely hinge on legal outcomes surrounding the acquisition terms rather than operational performance.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
